Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Allergan

Status and phase: Completed; Phase 3

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: brimonidine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00168363

190342-022

Details and patient eligibility

About

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Enrollment: 207 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ocular hypertension or glaucoma in both eyes
• currently treated with brimonidine
• requires IOP-lowering therapy in both eyes

Exclusion criteria

• uncontrolled systemic disease
• known allergy or sensitivity to brimonidine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind